BioCentury
ARTICLE | Company News

Janssen submits simeprevir MAA

April 25, 2013 12:01 AM UTC

The Janssen-Cilag International N.V. unit of Johnson & Johnson (NYSE:JNJ) submitted an MAA to EMA for simeprevir ( TMC435) to treat HCV genotype 1 and genotype 4 infection. In March, J&J's Janssen Res...